Therapeutic Potential of Lipoprotein(a) Inhibitors

Growing evidence has linked lipoprotein(a) [Lp(a)] to the development of atherosclerosis and calcific aortic stenosis, sparking significant interest in incorporating Lp(a) into cardiovascular prevention strategies. Current guidelines recommend universal measurement of Lp(a) levels, which could refine cardiovascular risk assessment and guide the use of more intensive preventive therapies for higher-risk patients. Concurrently, substantial efforts are underway to develop new therapeutics aimed at selectively and significantly lowering Lp(a) levels. Early studies involving antisense oligonucleotides (e.g., mipomersen, pelacarsen), RNA interference agents (e.g., olpasiran, zerlasiran, lepodisiran), and small molecule inhibitors (e.g., muvalaplin) have shown promising results in reducing Lp(a) levels with good tolerability. These agents are advancing in clinical trials to determine if lowering Lp(a) can effectively reduce cardiovascular risk. The outcomes of these studies could potentially revolutionize our approach to LY3473329 cardiovascular disease prevention.